StockNews.AI
MIST
StockNews.AI
55 mins

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

1. MIST will present at the AHA Scientific Sessions 2025 in November. 2. Presentation will focus on efficacy and safety of etripamil for PSVT. 3. MIST recently submitted a New Drug Application for etripamil to the FDA. 4. The conference occurs from November 7-10 in New Orleans. 5. Data concerns self-administered etripamil for a heart condition.

3m saved
Insight
Article

FAQ

Why Bullish?

MIST's NDA submission and upcoming presentation may positively influence investor confidence, similar to past biotech presentations that led to stock price increases upon positive trial data releases.

How important is it?

The significant focus on etripamil could change market perception, thus impacting MIST’s stock value based on investor sentiment.

Why Short Term?

The upcoming presentation is imminent and could influence MIST's stock performance shortly thereafter, aligning with historical patterns where conference presentations move stock prices quickly.

Related Companies

VRTXALNYMDGL
October 09, 2025 08:00 ET  | Source: Milestone Pharmaceuticals Inc. MONTREAL and CHARLOTTE, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a poster presentation at the American Heart Association Scientific Sessions 2025, to be held November 7-10th in New Orleans, Louisiana. Data to be presented describe the efficacy, safety, and tolerability of self-administered etripamil by patients with episodes of paroxysmal supraventricular tachycardia. AHA 2025 Presentation Details: Poster Presentation Title:Combined Efficacy, Safety, and Test Dose Tolerability of Etripamil for Acute Paroxysmal Supraventricular Tachycardia (PSVT) Across Multiple Clinical TrialsPresenter:James Ip, M.D., Associate Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian HospitalDate and time:Monday, November 10, 2025, 10:30 – 11:30 AM CST   About Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for treatment of an abnormal heart rhythm, paroxysmal supraventricular tachycardia or PSVT. Investor Relations Kevin Gardner, kgardner@lifesciadvisors.com

Related News